The company is to start a pivotal Chinese trial of its PD-1 x TGF-β-targeting fusion protein.
ApexOnco Front Page
Recent articles
After menin, the company tries again with farnesyl transferase.
The second line shows no respite for Merck & Co's ROR1-targeting ADC.
Summit gatecrashes ASCO, but Harmoni shows no OS benefit and a large patient overlap.
Crunch time approaches for UroGen.
The combined company's MALT1 inhibitor has started phase 1.
Lilly, Merck & Co and Verastem could take on Amgen, Bristol and Revolution.
Meanwhile, Pfizer reckons it's found the right dose for its KAT6.
